A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

@article{Tariot2000A5R,
  title={A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.},
  author={Pierre N. Tariot and Paul R. Solomon and John C. Morris and Paul R Kershaw and Sean Lilienfeld and Chong-biao Ding},
  journal={Neurology},
  year={2000},
  volume={54 12},
  pages={2269-76}
}
OBJECTIVE To investigate the efficacy and tolerability of galantamine, using a slow dose escalation schedule of up to 8 weeks, in 978 patients with mild to moderate AD. METHODS A 5-month multicenter, placebo-controlled, double-blind trial. Following a 4-week placebo run-in, patients were randomized to one of four treatment arms: placebo or galantamine escalated to final maintenance doses of 8, 16, or 24 mg/day. Outcome measures included the cognitive subscale of the AD Assessment Scale (ADAS… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
204 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 204 extracted citations

Similar Papers

Loading similar papers…